PD01.05
Background: We reviewed the outcome of 10 years of investment in HIV new prevention technology (NPT) research including vaccine, microbicides and Pre-exposure prophylaxis (PrEP) in Uganda to identify areas of impact.
Methods: In-depth interviews and focus group discussions were held with 19 key informants using the Research Impact Framework (London School of Hygiene and Tropical Medicine) to identify where HIV NPT investment has had the greatest impact. Secondary data was collected from four key research institutions in Uganda.
Results: Investment in NPT research from 2001–2012 has had a positive impact in Uganda. Respondents highlighted areas of high impact such as scientific contributions, including data demonstrating efficacy of Voluntary Medical Male Circumcision and PrEP; improved understanding of key populations epidemiology and increased scientific productivity as evidenced by increased publications. There have been significant gains in skills development and expansion of expertise; more than 1,000 clinicians, nurses, and counselors trained in Good Clinical Practice, specialized training of more than 800 lab scientists and technicians and sponsorship of more than 50 higher degrees. Improved clinical trial infrastructure and standards of community engagement were also highlighted.
The investment impact was less than anticipated in the area of health system strengthening. Health benefits were limited to volunteer populations and to facilities in the vicinity of trial sites. In a few cases, improvements were not sustainable, expiring once projects were completed. Some respondents perceived international collaborations as being driven by external priorities resulting in upstream research and early product development being deprioritized.
Conclusions: There have been clear benefits to HIV NPT research investment in Uganda. Future investments should consider how to incorporate objectives of local investigators, including upstream research, and ensure the sustainability of health system strengthening.
